Epicelya Therapeutics AG

Epicelya Therapeutics AG is at the forefront of biotechnology research, dedicated to pioneering the future of genetic healthcare. Focused on precision medicine, Epicelya Therapeutics AG is committed to developing mRNA-based therapeutics that target diseases previously considered "undruggable." Their innovative approach aims to address the most challenging conditions, particularly in oncology and age-related diseases, where traditional treatments have limitations.

Through precision epigenetics and targeted cell elimination platforms, Epicelya Therapeutics AG strives to provide solutions where suitable targets were previously unattainable. The company’s mission is to retool genetic healthcare, advancing mRNA-based solutions with a focus on areas where there is significant unmet medical need. Epicelya Therapeutics AG is dedicated to making a meaningful impact on patients' lives through cutting-edge research and therapeutic development.

Located in the dynamic pharma-biotech hub of Basel, Switzerland, Epicelya Therapeutics AG is strategically positioned to drive scientific innovation and collaboration. The company is committed to pushing the boundaries of what's possible in genetic medicine. We invite the manager of Epicelya Therapeutics AG to create a customized and exclusive company showcase and product listing on our platform, so we can complete the information with their support.